Cargando…

SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore

Background: We evaluated the post-booster (BNT162b2) antibody responses in Singapore. Methods: Participants (n = 43) were tested pre-booster and 20/30/60/90 days post-booster. Participants were boosted 120–240 days (mean 214 days) after their second dose and had no history or serologic evidence of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Chin Shern, Phua, Soon Kieng, Liang, Ya Li, Oh, May Lin Helen, Aw, Tar Choon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879250/
https://www.ncbi.nlm.nih.gov/pubmed/35214789
http://dx.doi.org/10.3390/vaccines10020331
_version_ 1784658853970837504
author Lau, Chin Shern
Phua, Soon Kieng
Liang, Ya Li
Oh, May Lin Helen
Aw, Tar Choon
author_facet Lau, Chin Shern
Phua, Soon Kieng
Liang, Ya Li
Oh, May Lin Helen
Aw, Tar Choon
author_sort Lau, Chin Shern
collection PubMed
description Background: We evaluated the post-booster (BNT162b2) antibody responses in Singapore. Methods: Participants (n = 43) were tested pre-booster and 20/30/60/90 days post-booster. Participants were boosted 120–240 days (mean 214 days) after their second dose and had no history or serologic evidence of prior COVID-19 infection; all participants had undetectable SARS-CoV-2 nucleocapsid antibodies throughout the study. Total nucleocapsid and spike antibodies (S-Ab) were assessed on the Roche Elecsys e802 and neutralizing antibody (N-Ab) on the Snibe quantitative N-Ab assay. Results: Pre-booster median S-Ab/N-Ab titers were 829 BAU/mL/0.83 µg/mL; 2 participants were below manufacturer’s N-Ab cut-offs of 0.3 µg/mL (0.192 and 0.229). Both S-Ab and N-Ab titers peaked at 30 days post-booster (median S-Ab 25,220 BAU/mL and N-Ab 30.3 µg/mL) at 30–37× pre-booster median levels. These peak post-booster S-Ab/N-Ab titers were 11× (25,220 vs. 2235 BAU/mL) and 9× (30.3 vs. 3.52 µg/mL) higher than the previously reported peak post-second dose levels. Antibody titers declined to 12,315 BAU/mL (51% decrease) and 14.3 µg/mL (53% decrease) 90 days post-booster. Non-linear regression estimates for S-Ab/N-Ab half-lives were 44/58 days. At 180 days post-booster, S-Ab/N-Ab are estimated to be 2671 BAU/mL/4.83 µg/mL. Conclusions: Both S-Ab and N-Ab show a good response following post-booster vaccination, with half-lives that may provide a prolonged antibody response.
format Online
Article
Text
id pubmed-8879250
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88792502022-02-26 SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore Lau, Chin Shern Phua, Soon Kieng Liang, Ya Li Oh, May Lin Helen Aw, Tar Choon Vaccines (Basel) Article Background: We evaluated the post-booster (BNT162b2) antibody responses in Singapore. Methods: Participants (n = 43) were tested pre-booster and 20/30/60/90 days post-booster. Participants were boosted 120–240 days (mean 214 days) after their second dose and had no history or serologic evidence of prior COVID-19 infection; all participants had undetectable SARS-CoV-2 nucleocapsid antibodies throughout the study. Total nucleocapsid and spike antibodies (S-Ab) were assessed on the Roche Elecsys e802 and neutralizing antibody (N-Ab) on the Snibe quantitative N-Ab assay. Results: Pre-booster median S-Ab/N-Ab titers were 829 BAU/mL/0.83 µg/mL; 2 participants were below manufacturer’s N-Ab cut-offs of 0.3 µg/mL (0.192 and 0.229). Both S-Ab and N-Ab titers peaked at 30 days post-booster (median S-Ab 25,220 BAU/mL and N-Ab 30.3 µg/mL) at 30–37× pre-booster median levels. These peak post-booster S-Ab/N-Ab titers were 11× (25,220 vs. 2235 BAU/mL) and 9× (30.3 vs. 3.52 µg/mL) higher than the previously reported peak post-second dose levels. Antibody titers declined to 12,315 BAU/mL (51% decrease) and 14.3 µg/mL (53% decrease) 90 days post-booster. Non-linear regression estimates for S-Ab/N-Ab half-lives were 44/58 days. At 180 days post-booster, S-Ab/N-Ab are estimated to be 2671 BAU/mL/4.83 µg/mL. Conclusions: Both S-Ab and N-Ab show a good response following post-booster vaccination, with half-lives that may provide a prolonged antibody response. MDPI 2022-02-18 /pmc/articles/PMC8879250/ /pubmed/35214789 http://dx.doi.org/10.3390/vaccines10020331 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lau, Chin Shern
Phua, Soon Kieng
Liang, Ya Li
Oh, May Lin Helen
Aw, Tar Choon
SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore
title SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore
title_full SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore
title_fullStr SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore
title_full_unstemmed SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore
title_short SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore
title_sort sars-cov-2 spike and neutralizing antibody kinetics 90 days after three doses of bnt162b2 mrna covid-19 vaccine in singapore
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879250/
https://www.ncbi.nlm.nih.gov/pubmed/35214789
http://dx.doi.org/10.3390/vaccines10020331
work_keys_str_mv AT lauchinshern sarscov2spikeandneutralizingantibodykinetics90daysafterthreedosesofbnt162b2mrnacovid19vaccineinsingapore
AT phuasoonkieng sarscov2spikeandneutralizingantibodykinetics90daysafterthreedosesofbnt162b2mrnacovid19vaccineinsingapore
AT liangyali sarscov2spikeandneutralizingantibodykinetics90daysafterthreedosesofbnt162b2mrnacovid19vaccineinsingapore
AT ohmaylinhelen sarscov2spikeandneutralizingantibodykinetics90daysafterthreedosesofbnt162b2mrnacovid19vaccineinsingapore
AT awtarchoon sarscov2spikeandneutralizingantibodykinetics90daysafterthreedosesofbnt162b2mrnacovid19vaccineinsingapore